New Prospects in Blood-based Biomarkers and Disease-Modifying Anti-Amyloid Antibody Therapies for Early-Stage Alzheimer’s Disease
CME | 1.50 Credits Webcast Time to Complete: 90 minutes Released: February 16, 2024 Expires: February 16, 2025 Maximum Credits: 1.50 / AMA PRA Category 1 CreditsTM Program Description This webcast provides an update on the blood-based markers (BBMs) improve randomized clinical trials (RCTs) design and conduct of Alzheimer’s disease. It remains to be determined if the data available…